A novel virus-free anticancer gene therapy by combining RNAi interference technology with a tissue-specific delivery system.
發展階段｜STAGE OF DEVELOPMENT
Ready to launch
- Safe: Virus-free and Reversible, safe for both patients and operators
- Precise: Tumour-specifically release the genetic modifiers, avoiding side-effects to normal tissues
- Flexible: Can target any gene, including the newly identified isoforms
如何解決市場痛點｜RESPONSE TO MARKET PAIN POINTS
Gene therapy can utilize viruses to modify diseased genes to eradicate cancer, but the use of viral vectors have certain clinical safety risks. The CU Medicine research team have invented a novel virus-free anticancer gene therapy for regulating gene expression without using a virus.
By combining RNAi interference technology and ultrasonic microbubble delivery system, shRNA-expressing plasmids can be tumor-specifically released to inhibit the expression of diseased gene(s), representing a controllable anticancer gene therapy. This invention can serve as a rapid evaluating platform for new therapeutic targets preclinically, as well as further development towards a safe anticancer gene therapy clinically.
- 資金 Funding
- 曝光機會 Visibility and Exposure